PDL BioPharma, Inc. canceled production of visilizumab following its Phase II/III clinical trials, citing its inefficacy and poor safety profile compared to other drugs on the market as the major reasons.
PDL BioPharma, Inc. made the decision to discontinue visilizumab production after its Phase II/III clinical trials, mainly because it was deemed less effective and more hazardous than competing medications on the market.